Compare Eos Energy Enterprises Inc (EOSE) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eos Energy Enterprises Inc vs Novo Nordisk A/S — how do they compare? Eos Energy Enterprises Inc trades at $4.18 (market cap $1.55B), while Novo Nordisk A/S trades at $51.5 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 143.4× Eos Energy Enterprises Inc's market cap, and Novo Nordisk A/S pays a 3.56% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals.
| EOSE | NVO | |
|---|---|---|
Market Cap | $1.55B | $222.24B |
Sector | Energy | Health |
52-Week High | $19.19 | $71.70 |
52-Week Low | $4.29 | $35.29 |
Enterprise Value | $1.79B | $241.20B |
Dividend Yield | — | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $4.21, down 1.86% on the day, amid a bearish technical signal. The company reported a net loss of $969.65 million on $114.20 million revenue in 2025, with negative gross and net profit margins, but revenue growth is accelerating into 2026. Recent news highlights record quarterly revenue expectations and a $125 million investment for Frontier Power USA, signaling strong commercial momentum.
The outlook is mixed: accelerating revenue and a growing project backlog offer upside potential, but persistent losses and high debt-to-asset ratio of 91.87% pose significant financial risks. Analyst consensus is a 'Hold' with a $9.00 price target, reflecting cautious optimism balanced by execution concerns in the competitive energy storage market.
Novo Nordisk (NVO) trades at $49.07, down 0.43% on the day, amid a bullish technical signal and strong fundamental performance. The stock exhibits robust profitability with a 37.2% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights EU approval for its Wegovy weight-loss pill, reinforcing its competitive position in the GLP-1 market.
The outlook remains positive given earnings momentum and expanding product approvals, though risks include rising competition from generics and potential prescription slowdowns. Analyst consensus is bullish with 57.9% buy ratings, supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
